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Objectives: The aim of this study was to assess the impact of the advanced
technology of the new ExAblate 2100 system (Insightec Ltd, Haifa, Israel) for
magnetic resonance imaging (MRI)Yguided focused ultrasound surgery on
treatment outcomes in patients with symptomatic uterine fibroids, as measured
by the nonperfused volume ratio.
Materials and Methods: This is a retrospective analysis of 115 women
(mean age, 42 years; range, 27Y54 years) with symptomatic fibroids who
consecutively underwent MRI-guided focused ultrasound treatment in a single
center with the new generation ExAblate 2100 system from November 2010 to
June 2011. Mean T SD total volume and number of treated fibroids (per pa-
tient) were 89 T 94 cm3 and 2.2 T 1.7, respectively. Patient baseline char-
acteristics were analyzed regarding their impact on the resulting nonperfused
volume ratio.
Results: Magnetic resonance imagingYguided focused ultrasound treatment
was technically successful in 115 of 123 patients (93.5%). In 8 patients,
treatment was not possible because of bowel loops in the beam pathway that
could not be mitigated (n = 6), patient movement (n = 1), and system mal-
function (n = 1). Mean nonperfused volume ratio was 88% T 15% (range,
38%-100%). Mean applied energy level was 5400 T 1200 J, and mean number
of sonications was 74 T 27. No major complications occurred. Two cases of
first-degree skin burn resolved within 1 week after the intervention. Of the
baseline characteristics analyzed, only the planned treatment volume had a
statistically significant impact on nonperfused volume ratio.
Conclusions: With technological advancement, the outcome of MRI-guided
focused ultrasound treatment in terms of the nonperfused volume ratio can be
enhanced with a high safety profile, markedly exceeding results reported in
previous clinical trials.
Key Words: MRI-guided focused ultrasound, leiomyoma, uterine fibroid,
ablation, nonperfused volume
(Invest Radiol 2013;48: 359Y365)
U terine leiomyomas (fibroids) represent a common benign myo-metrial tumor found in 25% to 77% of women of childbearing
age.1,2 Symptoms occur in approximately 25% of the female popu-
lation with fibroids, including menorrhagia, dysmenorrhea, bulk-
related symptoms such as pelvic pain and an increased urinary fre-
quency, and infertility. Besides hysterectomy and myomectomy,
minimally invasive surgical techniques such as hysteroscopic or
laparoscopic myomectomy and uterine artery embolization have be-
come available.3 However, postprocedural pain and fever are com-
mon with patients undergoing a recovery period of up to several
weeks.4 Moreover, severe periprocedural complications have been
observed.5,6
Magnetic resonance imaging (MRI)Yguided focused ultra-
sound (MRgFUS) surgery is a noninvasive thermal ablation tech-
nology for percutaneous high-intensity focused ultrasound tumor
ablation under Magnetic Resonance Imaging Guidance and Thermal
Monitoring.7 The MRgFUS device ExAblate 2000 (InSightec Ltd,
Haifa, Israel) was approved by the US Food and Drug Administration
(FDA) in 2004 for the treatment of symptomatic uterine fibroids.
During MRgFUS treatment, a high-intensity focused ultrasound
beam induces the selective, rapid heating of multiple sequential foci
leading to thermocoagulation only within the targeted tumor tissue
while neighboring structures along the beam path are preserved.8 The
combination of the heat-generating focused ultrasound technology
with a magnetic resonance (MR) system allows for the anatomically
precise definition of a target volume, real-time thermal monitoring of
the ablation process, and postprocedural evaluation of the treatment
result.
In women with symptomatic uterine fibroids, the coagulative
necrosis, followed by a gradual resorption, size reduction, and func-
tional loss of the fibroid tissue, accounts for an effective relief of
symptoms.9,10 Morphologically, the success of MRgFUS treatment
can be assessed by calculating the nonperfused volume (NPV) ratio
(ie, the posttreatment ratio of nonperfused fibroid volume divided by
the pretreatment fibroid volume). It has been shown that a higher
NPV ratio is correlated with a better reduction in fibroid-related
symptoms and a reduced probability of further fibroid treatments.11
Several anatomical and technical constraints have repeatedly
been reported that impeded optimization of the NPV ratio in a sig-
nificant ratio of patients12: Bowel loops are impassable by the fo-
cused ultrasound beam and may be interposed between the transducer
and the fibroid, requiring particular mitigation techniques or pre-
cluding any treatment. Treating fibroids near the sacrum may be
painful because of far-field heating of the neighboring sacral
nerves.13,14 In case of patient movement, the entire treatment plan has
to be adapted, increasing the overall patient time on the treatment
table. Large fibroids require large sonication spot sizes to cover their
volume and avoid 2 sonication layers. Fibroids with a high signal
intensity (SI) in T2-weighted (T2w) MRI seem to be less susceptible
to efficient MRgFUS treatment.15,16
To overcome the above-mentioned limitations, several techni-
cal modifications and improvements have been implemented in the
new generation ExAblate 2100 system. These include a transducer
that can be elevated closer to the abdominal wall, allowing for re-
duced energy density in the near- and far-field; a decreased average
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focal distance; and an increased maximum energy level. Selective
transducer elements are automatically disabled by the system in case
risk structures are detected in the beam path. Together with an im-
proved energy dispersion, the maximum sonication spot size has been
enlarged to 70 mm to facilitate treatment of larger fibroid volumes.
Moreover, a 3-dimensional treatment planning software optimizing
the use of different spot sizes and energy levels has been introduced.
In case patient movement is detected by the system during the
treatment, the primary treatment plan can be directly transferred to
the newly acquired T2w planning images.
Besides technological advances, mitigation techniques such as
rectal filling with ultrasound gel, introducing inflatable balloons into
the rectum, and bladder filling with sterile saline to push the uterus
anteriorly and to minimize the presence of bowel loops along the
beam path have been developed. In addition, patient management
techniques were optimized to reduce the preparation time, patient
pain, and movement.14
In this article, we report the NPV and safety results of, to the
best of our knowledge, the first 115 patients who were treated with
the new ExAblate 2100 system in a single center.
MATERIALS AND METHODS
Patients
This study includes all patients who completed MRgFUS
treatment of symptomatic uterine fibroids using the ExAblate 2100
system (InSightec Ltd) from November 2010 to June 2011 in a single
center. Because this study was a retrospective analysis, approval by
the local ethical committee was not required. The principles of the
Declaration of Helsinki were followed. Indication for MRgFUS
treatment was regularly confirmed by a multidisciplinary team of
interventional radiologists and gynecologists in accordance with se-
lection criteria published elsewhere.13,14 Pregnant women and those
with a contraindication to MRI were excluded. Women with the de-
sire for future pregnancy were counseled with respect to the limited
data for pregnancy after MRgFUS treatment.17 Relative exclusion
criteria, according to the screening MRI examination, were exten-
sive scars within the anterior abdominal wall, bowel interposed along
the ultrasound beam pathway, and fibroids located near the sacral
surface.
A total of 123 women with symptomatic uterine fibroids were
consecutively admitted for MRgFUS treatment. All patients had un-
dergone a screening MRI examination to determine the suitability
and accessibility for MRgFUS treatment and to confirm the corre-
lation with the patients’ symptoms.
Table 1 shows the baseline characteristics of the patient cohort
(n = 115) who completed treatment. In 45 patients, 1 symptomatic
fibroid was treated; in 43 patients, 2 to 4 fibroids; and in 27 patients,
5 or more symptomatic fibroids. Table 2 shows the size distribution
of the treated fibroids.
Treatment Device
The MRgFUS device operates in conjunction with a standard
1.5-T MRI system (General Electric HealthCare, Milwaukee, WI) for
preprocedural and postprocedural image acquisition, as well as for
intraprocedural image guidance with thermal MR images.18 In
comparison with the ExAblate 2000 system, the second-generation
ExAblate 2100 UF V2 system is characterized by the following
technical properties:
& The transducer can be elevated closer to the abdominal wall (within
a 4-cm distance from the patient skin). Together with a reduced
thickness of the gel pad of 2.5 cm (previously 4 cm), the energy
density on the patient skin and on the sacral nerves is reduced, making
treatment near these sensitive regions feasible. As a consequence,
at the same time, the average focal distance has been reduced from
17 to 11.5 cm (Figs. 1A, B).
& In case the planned ultrasound beam path passes through risk
structures such as bowels or pubic bone, selective transducer ele-
ments are automatically disabled by the system (Fig. 1C, D).
& Larger sonication spots (length up to 70 mm; previously 45 mm),
combined with an improved energy dispersion, allow for the ab-
lation of larger fibroid volumes within the same time frame. The 3-
dimensional treatment planner optimizes the use of different spot
sizes and energy levels within a drawn treatment volume (Fig. 1E)
& The maximum energy level of sonications has been increased to
7200 J.
& In case of patient movement during the treatment, the primary
treatment plan (ie, drawing of the treatment volume and risk
structures) can be transferred to the newly acquired T2w images to
account for the changed anatomical situation.
MRgFUS Treatment
Informed consent was obtained from all patients 24 hours and
directly before the MRgFUS intervention after extensive explanation
of the method, its potential complications, and alternative treatments.
On the treatment day, patients were prepared for the MRgFUS pro-
cedure as previously reported.9,11,19Y21 After patient positioning on
the treatment table, localizer images were acquired to verify uterine
TABLE 1. Baseline Characteristics of the MRgFUS Treatment
Group (n = 115)
Characteristic
Age, y 42.4 T 6.4












Diameter of the largest fibroid, cm 5.4 T 2.2
SI (T2w) of the largest fibroid*
Type 1 84 (73)
Type 2 31 (27)
Fibroid structure (largest fibroid)
Homogeneous 62 (53.9)
Heterogeneous 53 (46.1)
Contrast enhancement of the largest fibroid
Lower than myometrium (type 1) 71 (61.7)




Bulk-related symptoms 44 (38.3)
Not specified 19 (16.5)
Data are presented as mean T SD or n (%).
*According to Funaki et al.15
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position and fibroid accessibility. If needed, mitigation techniques
were implemented to modify the uterine position to remove bowel
loops in the beam path. T2-weighted MR images were acquired in
3 planes for treatment planning. On all acquired images, the operat-
ing radiologist delineated the volume of the fibroids to be treated.
Sensitive organs were also highlighted. Then, the system automati-
cally created an optimized 3-dimensional treatment plan characterized
by sonication spots of different sizes, angles, and transducer apertures
to avoid transmission of the beam path through sensitive organs
(Fig. 1). After performing a low-energy test sonication to verify
system accuracy, therapeutic-level sonications were performed accord-
ing to the treatment plan in an interleaved mode. This is a technique that
minimizes the time for skin cooling between sonications. During
each sonication, gradient echo thermal images were obtained every
3.4 seconds, including a reference image before energy delivery
subsequently followed by several images to verify the correct energy
deposition within the targeted fibroid volume. The automatic soni-
cation energy level of the used ExAblate 2100 system was routinely
set to 120% (based on our clinical experience, this setting has been
proven to be safe and efficient); that is, an increased energy level
in relation to the system’s preset energy level was used. In addition,
the energy was optimized according to the fibroid characteristics
(ie, fibroid SI on T2w images and contrast enhancement on T1w
images), to achieve sufficient temperature rise. After treatment, all
patients were given 7.5 mL of contrast agent (Gadovist 1.0; Bayer
Schering Pharma AG, Berlin, Germany), and contrast-enhanced T1w
fat-suppressed MR images were acquired to quantify the NPV ratio
of all treated fibroids. Any adverse events (ie, skin burns, sciatica)
occurring during or immediately after the treatment were docu-
mented in the final radiologic report.
Assessment of Technical Treatment Outcome
The success of MRgFUS treatment was determined based on
the NPV ratio of the treated fibroids. The NPV ratio was measured
using the NPV after treatment, as measured by the posttreatment T1-
weighted contrast-enhanced MR images, divided by the treated fi-
broid volume, as measured by pretreatment T2w MR images. The
respective volumes were calculated by manual slice-by-slice area
measurements, multiplied by the slice thickness. Treatment was
regarded successful if an overall NPV ratio of 60% or more was
achieved. It has been shown that an NPV of more than 60% is
FIGURE 1. Technical properties of the system used. A and B, The transducer can be elevated to the abdominal wall within a 4-cm
distance (arrows). Together with a reduced thickness of the gel pad, the near- and far-field energy density is reduced. C and D,
Selective transducer elements are automatically disabled in case the ultrasound beam path (blue) passes through risk structures such
as bowel (arrows) or pubic bone. Panel C shows the sagittal view, whereas panel D shows the coronal view of the beam path, with
selectively disabled transducer elements being depicted as missing sector sections. E, 3-dimensional treatment planner: Longer
sonication spots (up to 70mm) combined with an improved energy dispersion allow for the ablation of larger fibroid volumes within
the same time frame. Different spot sizes and energy levels are used within a drawn treatment volume.





0Y50 25 55 (47.8)
51Y100 74 24 (20.9)
101Y150 123 16 (13.9)
151Y200 169 4 (3.5)
201Y250 218 5 (4.3)
251Y300 269 4 (3.5)
301Y350 326 3 (2.6)
351Y400 371 3 (2.6)
401Y450 418 1 (0.9)
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correlated with a probability of less than 15% of undergoing addi-
tional treatments during the 24 months posttreatment.11,19,20
Assessment of Clinical Treatment Outcome
Before treatment and at 6-month follow-up, patients were
asked to voluntarily complete the 8-item section of the Uterine Fi-
broid Symptom and Quality-of-Life questionnaire to assess a symp-
toms severity score (SSS) with respect to fibroid-related symptoms.
The follow-up questionnaires were collected by postal mail. The
presence and intensity of both bleeding and bulk-related symptoms
were assessed on a 5-point Likert scale (with responses in a range
from 1 = not at all to 5 = a very great deal). The sum of the scores was
transformed into a 0 to 100 scale for comparison, with 100 points
representing a maximum symptom severity.11
Statistical Analysis
For statistical analysis, IBM SPSS 20.0 for Windows (IBM
Corp, Armonk, NY) was used. A level of significance of > = 0.05
was used throughout the study.
Impact of Patient Baseline Characteristics on NPV Ratio
Several patient baseline characteristics were examined with
respect to their relation with the resulting NPV ratio. For that, the
following groups were formed and Student t tests were applied to
assess differences in the NPV (in case of interval-scaled variables,
the median value was chosen as limit):
& number of fibroids per patient (1 vs 91 fibroid)
& diameter of the largest fibroid (G5 vs Q5 cm)
& T2w SI of the largest fibroid (low SI [type 1] vs intermediate SI
[type 2])15
& homogeneity of the largest fibroid (homogeneous vs heterogeneous)
& contrast enhancement of the largest fibroid (lower thanmyometrium
[type 1] vs comparable with myometrium [type 2])
& planned treatment volume (G50 vs Q50 cm3)
& applied energy (G5500 vs Q5500 J)
& presence of bowel loops (with vs without use of mitigation
techniques)
Clinical Treatment Outcome
Data were initially assessed for normality with the Kolmogorov-
Smirnov test. On the basis of these results, we decided to use a
nonparametric procedure to compare the change in the transformed
SSSs. Therefore, the Wilcoxon signed-rank test was applied.
RESULTS
In a cohort of 123 women with symptomatic uterine fibroids
treated consecutively, MRgFUS treatment was successfully com-
pleted in 115 patients (93.5%) (Figs. 2 and 3). In 8 patients (6.5%),
treatment was not possible because of the following reasons: 6
patients presented with bowel in the beam pathway that could not be
mitigated by modification of the transducer or patient positioning
(using both bladder filling with saline and rectal filling with ultra-
sound gel, respectively). In 1 patient, the procedure had to be aborted
because of continuous patient movement despite conscious sedation.
In another patient, the treatment was not completed because of a
system malfunction.
Of the 115 treated patients, rectal filling with ultrasound gel
was applied in 64 (55.7%) patients and temporary filling of the
bladder using sterile saline was applied before treatment in 51
(44.3%) patients. A total of 48 patients (41.7%) received a combi-
nation of both. Rectal filling and bladder filling were performed only
for the purpose of removing bowel loops in front of the uterus. In
case the initial injection and reaspiration of sterile saline into the
bladder was not sufficient to move the bowel loops out of the beam
pathway, an additional rectal filling was administered to move the
uterus anteriorly. Only if the combination of temporary bladder fill-
ing and rectal filling failed to remove the interposed bowel loops was
an intraprocedural bladder filling used to create an acoustic treatment
window.
Eleven patients (9.6%) presented with scars of the abdominal
wall that were mitigated using a scar patch or through tilting of the
transducer.22
On average, 74 T 27 sonications (range, 20Y146) were per-
formed per treatment. Mean sonication time (ie, time from first to last
sonication) and overall procedure time (including patient positioning
and imaging) were 3.3 T 1.2 hours (range, 1.1Y6.6 hours) and 4.1 T
1.1 hours (range, 1.7Y6.8 hours), respectively. Mean applied energy
FIGURE 2. A 45-year-old woman with a 418-cm3 fibroid experiencing gradually worsening pelvic pressure and hypermenorrhea. A,
Sagittal T2w MR image obtained before treatment shows predominantly hypointense fibroid (type 1) with hyaline degeneration of
the central area. B, Sagittal contrast-enhanced fat-suppressed MR image before treatment shows homogeneous enhancement of
vital fibroid tissue. C, Sagittal contrast-enhanced fat-suppressed MR image acquired immediately after treatment shows a
completely nonperfused fibroid tissue.
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level was 5400 T 1200 J (range, 2500Y7400 J). Mean energy level
in fibroids with a low T2w SI (type 1) was 5400 T 1200 J (range,
2500Y7400 J) and in fibroids with an intermediate T2w SI (type 2)
was 5600 T 1000 J (range, 3600Y7100 J).
The mean total NPV ratio was 88% T 15% (range, 38%Y100%)
(Table 3). Ninety percent of the treated patients (n = 103) showed an
NPVof more than 60%.
The statistical analysis of the influence of patient baseline
characteristics on the NPV results was significant only for the
planned fibroid volume (P = 0.037), with better NPV results in fi-
broid volumes smaller than 50 cm3. Regarding the remaining base-
line characteristics (number of fibroids, diameter of largest fibroid
[Fig. 2], T2w SI of the largest fibroid, contrast enhancement of the
largest fibroid [Fig. 2], homogeneity of the largest fibroid [Fig. 3],
applied energy, and presence of intestine loops that could be miti-
gated), no significant difference was observed (Table 4).
Adverse Events
There were no serious adverse events observed during or after
the treatments. Two treatments resulted in first-degree skin burns.
One patient with a fibroid characterized by an intermediate T2w SI
and an elevated contrast enhancement showed a skin erythema and a
small blister. The applied maximum energy level in this patient was
4600 J, which is well below the maximum energy level of 7100 J in
the corresponding subset of treated type 2 fibroids. The other patient
had a history of a previous cesarean section and had undergone
treatment with a scar patch. In this patient, the applied maximum
energy level was 6500 J, leading to a skin burn at the edges of the
patch. Both skin burns resolved without any interventions until the
1-week follow-up visit. There were no other procedure-related ad-
verse events or complications.
Clinical Treatment Outcome
After a mean follow-up period of 6.5 months, the SSS (median
value [25th percentile, 75th percentile]) of the 72 patients (62.6%)
who voluntarily sent back the questionnaire decreased significantly
(P G 0.0001) from 62.5 (37.5, 72.5) to 37.5 (25.0, 44.375).
DISCUSSION
To the best of our knowledge, this retrospective single-center
study presents the results of MRgFUS surgery of symptomatic
uterine fibroids performed in the first larger clinical series of 115
patients using the second-generation ExAblate 2100 system. In
comparison with its predecessor ExAblate 2000, in the new system,
several major technical modifications have been implemented to
compensate for both technical and anatomical limitations previously
restricting suitability and accessibility of symptomatic uterine
fibroids. In particular, these new technical features comprise a
transducer that can be moved closer (ie, up to 4 cm) to the abdominal
wall, reducing energy density on the patient skin and on the sacral
nerves. The selective disabling of transducer elements facilitates
sonications close to sensitive structures such as bowel loops delin-
eated in the treatment plan. The maximum sonication spot size has
been increased from 45 to 70 mm to allow for the treatment of larger
fibroid volumes within the same time frame. Whereas in the first-
generation system, the primary treatment plan was characterized by
standard sonication spots regarding size and energy level (often re-
quiring a manual optimization of each sonication by the operator),
the 3-dimensional treatment planning software automatically fills out
the delineated volume of treatment with different sonication spot
sizes and energy levels, which accelerates the approval of the indi-
vidual sonications by the operator and helps to reduce the total
treatment time. The transfer of the primary treatment plan onto the
newly acquired T2w planning images in case of patient movement
contributes to further decrease the total procedure time. Although the
new MRgFUS system allows for an increased maximum sonication
energy of 7200 J, only 2 minor skin burns were observed in our pa-
tient cohort.
With increasing experience and the implementation of new
techniques and technologies, the NPV ratio measured immediately
TABLE 3. Distribution of NPV Ratio of Fibroids Immediately After




0Y25 0 0 (0)
26Y50 45.8 6 (5.2)
51Y75 66.5 18 (15.5)
76Y100 94.3 91 (79.4)
FIGURE 3. A 34-year-old woman with 75 cm3 of fibroid tissue experiencing hypermenorrhea. A, Sagittal T2w MR image obtained
before treatment shows several hypointense intramural fibroids. B, Sagittal contrast-enhanced fat-suppressed MR image before
treatment shows a strong enhancement of the vital fibroid tissue. C, Sagittal contrast-enhanced fat-suppressed MR image acquired
after treatment. Because of strong vascularity of fibroid tissue and intramyomal septations, an NPV ratio of only 51% was achieved.
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after MRgFUS treatment has increased.20 This NPV ratio has been
shown to be a predictor of both fibroid volume and symptom re-
duction,11,23 which suggests a strong correlation between the success
of MRgFUS treatment and devascularization, as has been suggested
in uterine fibroid embolization.24
Early clinical studies conducted before FDA approval of the
first-generation ExAblate 2000 system were limited by several re-
strictive safety measures to minimize the likelihood of adverse
events. These included a restriction of treatment volume (to 100 cm3
and 33% of the total fibroid volume, respectively) and a limitation of
treatment duration to a total table time of 3 hours.9,11 Stewart et al11
reported that 57% of the patients treated under these restricted
guidelines had an NPV ratio of 20% or less, and fewer than 3% of the
patients had an NPV ratio of 70% or more.
The growing experience with MRgFUS treatment along with
the implementation of the less restrictive modified FDA commercial
treatment guidelines facilitated improved clinical results while
maintaining a high safety profile of the technique.19,25,26
In their cohort of 80 patients, applying more relaxed treatment
guidelines, LeBlang et al25 achieved a mean NPV ratio of 55%. For
all groups of fibroids, independent of size, it was possible to obtain
an NPV ratio of at least 50%, whereas larger NPV ratios of more than
60% were predominantly seen after treatment of smaller fibroid
volumes (ie, G100 cm3). The authors reported 2 cases of first-degree
skin burns and 1 case of mild sciatica.
Morita et al26 retrospectively analyzed 83 patients to deter-
mine the safety of treating closer to the serosal surface and thereby
increasing the treatment volume. Measuring the distance between the
treatment spots and the serosa, they found that 79% and 37% of the
sonications were located less than 15 and 10 mm from the serosal
surface, respectively. During a 1-year follow-up period, the authors
observed no unexpected or serious adverse events.
In our institution, we applied a minimum spot distance of 5 mm
from the serosal surface, which provided an expanded treatment vol-
umewith no concurrent serious adverse events observed. AsMorita et
al26 stressed, the distance between the sonication spot and the serosa
should be determined on a case-by-case basis (eg, in case of fibroids
close to the serosal surface) by careful assessment of neighboring
sensitive structures such as bowel in the pretreatment MR images. In
our experience, potential damage can be circumvented by using small
or tilted spots and by paying special attention to the spot location
using the real-time temperature maps and the anatomical images to
verify that no patient movement has occurred.
The recent work by Okada et al20 has underlined the impact of
the learning curve on the technical outcome and complication rates of
MRgFUS over time. Their retrospective evaluation included 287
patients who underwent treatment of uterine fibroids with ExAblate
2000 in 4 different Japanese institutions over a 4-year period. The
authors found a significant (P G 0.001) increase in the NPV ratio
from 39.3% (first 2-year period) to 54.0% (second 2-year period) and
a significant reduction in the proportion of patients who underwent
alternative treatments at 1-year follow-up (9% vs 4.2%). Further-
more, the skin burn profile markedly improved, with a 5-fold fre-
quency of skin burns (n = 10) observed in the first period. These
results correspond to our observations, as NPV results have also
markedly improved in our institution with increased operator
experience.
Technical modifications of the ExAblate 2000 device already
improved treatment outcomes through the introduction of reduced
intersonication cooling times for sonications located a large distance
apart, as well as enlarged focal regions through enhanced beam
steering during sonication.23 The 3-dimensional planning software
introduced with the second-generation ExAblate 2100 system, used
in our study, automatically generates a plan that enhances the NPV,
through the use of angled ultrasound beam targeting, optimization of
the spot energy and distribution, adequate packing of the planned
sonications, and ablation of all accessible fibroid regions.20
However, there are still various patient- and fibroid-related
factors that may negatively influence the eligibility and accessibility
of patients, and affect the technical outcome of the MRgFUS pro-
cedure, or require particular mitigation techniques before treat-
ment.14,27 As Funaki et al15 showed, the efficacy of MRgFUS
correlates with the fibroid SI on T2w MR images, suggesting an
increased fibroid vascularity.28 In type 1 (low T2 SI) and 2 (inter-
mediate T2 SI) fibroids, the technically achievable NPV ratio is
comparable. However, type 3 (high T2 SI) fibroids are characterized
by a significantly lower NPV ratio,16 a higher necessary level of
mean acoustic power,23 and a higher reintervention rate.29,30
In our patient cohort, we observed a markedly increased mean
NPV ratio compared with previously reported results,11,20,25,29 with a
high safety profile. Baseline characteristics that had been considered
as limiting factors of MRgFUS treatments, such as large number of
fibroids, fibroids with high T2w SI or heterogeneous fibroids, as well
as bowels lying in the ultrasound beam pathway, had no statistically
significant impact on the NPV results achieved.31 Moreover, in more
than half of the cases, mitigation techniques that have been developed
due to the experience collected in our hospital facilitated treatment of
patients not amenable to MRgFUS according to previously reported
criteria.31
Together with both the experience accumulated with the first-
generation MRgFUS system, ExAblate 2000, particularly regarding
the routine use of mitigation techniques, and a strict selection of
suitable patients, the combined technical improvements of the new
ExAblate 2100 system have markedly contributed to achieve the
improved results presented in this study. The larger spot types with an
improved energy dispersion profile have turned out to be particularly
advantageous in cases with large fibroid volume ablations. The
dedicated treatment planning schemes for fibroids with different
signal intensities allow for the effective treatment of ‘‘bright’’
fibroids. Moving the transducer closer to the patient enables a higher
energy density in the focus and, thus, an improved ablation. Selec-
tively shutting down transducer elements facilitates treatments close
to sensitive regions such as bowel loops.
Limitations
There are a few limitations that have to be underlined.
The current study presents only the immediate results of
MRgFUS treatment conducted with the ExAblate 2100 system in
TABLE 4. Impact of Baseline Characteristics on NPV Ratio
Characteristic P*
Presence of intestine loops that could be mitigated
(with vs without use of mitigation techniques)
0.999
Homogeneity of largest fibroid (homogeneous vs heterogeneous) 0.940
Number of fibroids per patient (1 vs 91 fibroid) 0.793
Applied energy (G5500 vs Q5500 J) 0.629
T2w SI of the largest fibroid (type 1 vs type 2)† 0.224
Contrast enhancement of the largest fibroid (type 1 vs type 2)‡ 0.056
Diameter of the largest fibroid (G5 vs Q5 cm) 0.051
Planned treatment volume (G50 vs Q50 cm3) 0.037
*A level of significance of > = 0.05 was used.
†Type 1, low T2w SI (comparable with that of skeletal muscle); type 2,
intermediate T2w SI (lower than myometrium, but higher than skeletal
muscle).15
‡Type 1, contrast enhancement lower than myometrium; type 2, contrast
enhancement comparable with myometrium.
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terms of the posttreatment NPV ratio of the treated fibroids as well as
regarding adverse events observed after the procedure. On the basis
of these initial results, we expect that symptom relief will be highly
effective and durable. However, it is important to examine the clinical
long-term effect of the high NPV ratios observed in our patient
cohort.11,29,32
Although to date (ie, May 2012), 8 of the 115 patients have
undergone a secondary MRgFUS treatment in our institution because
of recurrence of fibroid-related symptoms (corresponding to a 7%
MRgFUS reintervention rate), we did not perform a dedicated eval-
uation regarding the incidence of alternative surgical or minimally
invasive catheter-based treatments. The individual reasons for the
secondary MRgFUS treatments of the above-mentioned patients were
an incomplete primary ablation due to a location of the treated
fibroids in the posterior uterine wall near the sacrum (n = 3) or due to
a subserosal location (n = 3), a treatment of a small remaining fibroid
in a woman without clinical symptoms who wanted to get pregnant
(n = 1), and a planned secondary MRgFUS procedure in a patient
who had presented with a primarily inaccessible fibroid (n = 1).
CONCLUSIONS
This retrospective single-center analysis of, to our best
knowledge, the largest patient series treated with the ExAblate 2100
system to date shows that the outcome of MRgFUS treatment in
terms of the NPV ratio can be enhanced with a high safety profile,
markedly exceeding results reported in previous clinical trials. As
relief of fibroid-related symptoms is directly correlated with the NPV
ratio, the results achieved in our patient cohort are encouraging and
warrant further follow-up studies.
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